How to Increase Testosterone Naturally: An Evidence Guide for Men

Yes, but usually not the way gym folklore promises. The levers that work pull a suppressed level back toward normal. They do not push your normal testosterone to superhuman heights.

Here is what each lever does, in numbers:

Lever	Effect on testosterone	Evidence
Diet-driven weight loss	+2.5 to 2.9 nmol/L total testosterone	Umbrella review [2]
Weight-loss surgery	up to +8.7 nmol/L	Umbrella review [2]
Sleep 7 to 8 hours, not 5	5-hour nights cut it 10 to 15 percent in one week	Trial, 10 young men [1]
Stop regular heavy drinking	chronic drinking lowers total and free testosterone	Meta-analysis, 10,199 people [10]
Resistance training	no change in resting level (men 60+)	Meta-analysis [3]
Endurance or interval training	small rise in resting level (men 60+)	Meta-analysis [3]
CPAP for sleep apnea, alone	no significant change	Meta-analysis, 232 men [4]
Zinc	helps only with a deficiency	Systematic review [5]
Vitamin D	none to a small signal	RCT and meta-analyses [6][7][8]
D-aspartic acid, Tribulus	no proven rise	Trials and review [11][25][26]

The most reliable natural lever is losing visceral belly fat, the fat around your organs. In an umbrella review (an overview that pools many meta-analyses), diet-driven weight loss raised total testosterone by roughly 2.5 to 2.9 nmol/L (about 72 to 84 ng/dL) ^[2]. Large surgical weight loss raised it far more, up to about 8.7 nmol/L (around 250 ng/dL). The effect is biggest in men with a high BMI and a low baseline value.

These gains correct an obesity-suppressed level back up. The big numbers belong to the surgery league, not a 5-kilo cut in the gym. You are reclaiming what the fat suppressed. You are not building supernatural testosterone.

Why does belly fat come first? Because the biggest, best-evidenced effects sit here. Belly fat suppresses testosterone through several routes at once. Fat tissue converts testosterone into estradiol (a form of estrogen). The disturbed metabolism also dampens the control signals from the brain. That is why fat loss has the most reach, especially in men with a high BMI and a low baseline ^[2].

The second lever is sleep. Chronically short sleep measurably lowers testosterone. In a study of 10 healthy young men (mean age 24.3 years), researchers cut sleep to about 5 hours a night for one week. Daytime testosterone fell by 10 to 15 percent versus the well-rested baseline ^[1]. So seven to eight hours is not a wellness suggestion, it is endocrinology.

Now the most over-claimed point: resistance training does not meaningfully raise resting testosterone. A hard session produces a brief spike that returns to baseline within about 30 minutes. In a meta-analysis of men aged 60 and over, resistance training had no effect on basal testosterone. Endurance and interval training nudged it up slightly ^[3]. Train for strength, body composition and insulin sensitivity. Not as a testosterone pill.

And another myth: treating sleep apnea with CPAP (the breathing mask for nighttime breathing pauses) does not raise testosterone on its own. A meta-analysis of 7 studies in 232 men found no significant change in total testosterone after CPAP (standardized mean difference minus 0.14, a tiny effect; p = 0.558, easily explained by chance) ^[4]. The lever is the weight loss that often comes with it, not the mask itself.

Bottom line: the real natural levers are losing belly fat, sleeping 7 to 8 hours, cutting heavy drinking and training for general metabolic health. They restore a depressed level. Your genes and aging stay untouched. A replete, lean, well-rested man with moderate alcohol intake has basically used up his natural room to move. More optimizing then does little. The next level would be a medical question, not a lifestyle one. If you want to place this in the broader context of your 40s, the men 40-plus hub is worth a read.

The sobering answer first: no single food meaningfully raises a normal man's testosterone. Oysters, eggs and so-called testosterone foods are a myth. What matters is avoiding a real deficiency and avoiding heavy drinking.

Zinc only helps if you are zinc-deficient. A systematic review shows that serum zinc correlates with testosterone. Zinc supplementation raises testosterone in deficiency or disease states ^[5]. But the effect depends on dose and baseline. The human evidence base is thin (much of the review rests on animal data). So zinc is a deficiency correction, not a booster for replete men.

Vitamin D: mixed and weak evidence. Three analyses point in different directions:

• Graz RCT (a randomized controlled trial, the strongest study design; 98 healthy men, 20,000 IU per week for 12 weeks): no effect on total testosterone (median change plus 0.5 nmol/L; p = 0.497) ^[6].
• 2019 meta-analysis: also no effect (mean difference plus 0.20 nmol/L; p = 0.336) ^[7].
• Newer pooled analysis: a small positive signal (weighted mean difference 0.38; 95 percent CI, the plausible range, 0.06 to 0.70), mainly at doses above 4,000 IU a day taken for more than 12 weeks. It found no effect on free testosterone, LH, FSH or SHBG ^[8].

Verdict: if there is a benefit, it is small.

The German context: about 30 percent of adults in Germany have deficient vitamin D status (25-OH-D below 30 nmol/L), strongest in winter ^[9]. Correcting a true winter deficiency is reasonable on general grounds. As a testosterone strategy it does not hold up.

Alcohol lowers testosterone. This one is solid. A 2024 meta-analysis (21 studies, 30 trials, 10,199 subjects) found that chronic alcohol consumption significantly lowers total testosterone, free testosterone and SHBG, and raises estradiol ^[10]. The effect showed up in healthy men who drink regularly. It did not show up in cohorts with diagnosed alcohol use disorder or in studies of a single drinking session ^[10]. In practice: the regular after-work habit is what counts.

Testosterone booster supplements largely lack credible evidence. D-aspartic acid at 6 grams a day did not change basal total or free testosterone in resistance-trained men over three months ^[11]. In an earlier two-week trial, the same dose even lowered both ^[25]. Tribulus terrestris showed no reliable testosterone effect in a 2025 systematic review ^[26]. Treat over-the-counter testosterone boosters as unproven.

What is defensible on diet: enough protein, do not crash dietary fat toward zero, keep body fat down. That supports normal endocrine function. It is nothing more than that. One popular herbal booster, Tongkat Ali (Eurycoma longifolia), gets its own guide and we skip it here. Likewise, male-pattern hair loss (with finasteride or minoxidil) gets its own guide, because that is a different topic than the testosterone level itself.

Which symptoms point to low testosterone? The most specific ones are sexual: fewer morning erections, low sex drive and erectile dysfunction. In the EMAS study of European men aged 40 to 79, exactly these three tracked low testosterone best ^[13]. Tiredness, low mood, poor concentration, less muscle and more body fat also show up, but they are unspecific ^[12]. So symptoms raise the question. The blood test answers it.

The screening test is a fasting morning total testosterone. Testosterone fluctuates over the day and is highest in the morning, which is why timing matters. A single random value is no good for diagnosis.

A diagnosis of hypogonadism (a genuine testosterone deficiency) requires symptoms AND consistently low values, confirmed by a second fasting morning measurement ^[12]. Never a single blood draw. This double rule is the most important guard against misdiagnosis and premature therapy.

The Endocrine Society reference range (CDC-harmonized, healthy non-obese young men, 19 to 39 years): total testosterone 264 to 916 ng/dL (9.2 to 31.8 nmol/L). In practice, the lower cutoff to flag is 264 ng/dL, about 9.2 nmol/L ^[12].

Threshold	nmol/L	ng/dL	ng/mL
Lower limit, Endocrine Society [12]	9.2	264	2.64
Upper limit, Endocrine Society [12]	31.8	916	9.16
EMAS cutoff, late-onset hypogonadism [13]	11	317	3.2
TRAVERSE entry criterion [20]	10.4	300	3.0

The guideline sets no separate cutoff per age. Older men simply fall below it more often ^[12][13]. To convert, multiply ng/mL by 3.47 to get nmol/L.

Free testosterone and SHBG matter when total testosterone is borderline or SHBG is altered. SHBG (sex hormone-binding globulin) is the transport protein that binds testosterone in the blood. In that case, measure free testosterone by equilibrium dialysis (the reference lab method) or a validated calculation. Do NOT use a direct analog immunoassay, a cheap test that is unreliable here ^[12]. Obesity and diabetes lower SHBG. Aging, hyperthyroidism and alcohol-related liver disease raise it.

LH and FSH separate the cause. These are the control hormones from the pituitary gland. Low testosterone with high LH/FSH points to a primary problem in the testes. If it is low with low or normal LH/FSH, the secondary problem sits in the pituitary or hypothalamus, which matches the typical pattern in obesity and metabolic disorder ^[12].

How low is too low if you have symptoms? The EMAS study (European Male Ageing Study) set thresholds for symptomatic late-onset hypogonadism, the age-related form of testosterone deficiency. All three must apply ^[13]:

• total testosterone below 11 nmol/L (3.2 ng/mL)
• free testosterone below 220 pmol/L
• three sexual symptoms: poor morning erections, low libido and erectile dysfunction

A word on at-home tests. They exist, usually as a finger-prick blood kit you mail to a lab, some as a saliva test. The catch is not necessarily the reading. It is everything around it. A single home test cannot replace the full diagnostic logic ^[12]: symptoms, two fasting morning measurements and, if needed, free testosterone, SHBG, LH and FSH to find the cause. Saliva tests are not an established diagnostic method for testosterone anyway. A home test can be a prompt to take the value to a doctor. It is not a diagnosis.

On German access. Symptoms are what justify a diagnostic workup ^[12]. If you have them, your GP or urologist can order testosterone as part of that workup on statutory insurance (GKV). A pure curiosity check with no symptoms is usually self-pay or IGeL (an individual health service). The key point: symptoms plus two low morning values justify the workup, a single low value alone does not.

Yes, often years ahead. New-onset erectile dysfunction is the canary in the coal mine: an early marker of vascular and cardiovascular disease. The reason is anatomy. Small penile arteries become dysfunctional before the larger coronary arteries turn symptomatic.

The COBRA trial looked at men with chronic (stable) coronary disease who also had erectile dysfunction. In 93 percent of them, the erection problems came first, on average about 24 months earlier (range 12 to 36) ^[14]. For most of these men, the erection problem was the early warning for the later heart problem.

Erectile dysfunction also predicts future heart trouble on its own, largely independent of the classic risk factors. A meta-analysis of 12 prospective cohorts (36,744 men) found these risks for men with erectile dysfunction ^[15]:

• any cardiovascular disease: relative risk 1.48 (95 percent CI 1.25 to 1.74)
• coronary heart disease: RR 1.46 (1.31 to 1.63)
• stroke: RR 1.35 (1.19 to 1.54)
• death from any cause: RR 1.19 (1.05 to 1.34)

A relative risk of 1.48 means 48 percent more events than in men without erectile dysfunction. The CI (confidence interval) is the plausible range around that estimate.

The shared root is endothelial dysfunction (a disorder of the inner vessel wall) and the same risk factors: diabetes, smoking, high blood pressure, dyslipidemia, visceral obesity and a sedentary lifestyle. Treating these helps the erection and the heart at once. That is the real lesson: new erectile dysfunction is a reason to check blood pressure, glucose and lipids, not just to reach for a pill. More on this early-warning pattern sits in the men 40-plus hub.

Important for context: testosterone is NOT the go-to treatment for erectile dysfunction. Most men start with a PDE5 inhibitor (sildenafil and relatives), though the AUA guideline treats every suitable option as a valid starting point after a shared decision ^[16]. In men with normal testosterone, testosterone is not effective monotherapy for erectile dysfunction. It may be added in men with proven low testosterone to improve the response to the PDE5 inhibitor. So framing testosterone as a general erection drug is wrong.

The PSA test is useful, but not a free pass. PSA (prostate-specific antigen) is a blood marker that rises with prostate volume, inflammation and cancer, but it is not cancer-specific. Benign enlargement, prostatitis, and recent ejaculation or cycling also raise it. PSA is a screening trigger, not a diagnosis.

The screening benefit is real but modest. The central harm is overdiagnosis. In the European ERSPC trial, PSA screening cut prostate-cancer deaths by 13 percent after 23 years (rate ratio 0.87; 95 percent CI 0.80 to 0.95) ^[22]. That means 456 men had to be invited, and 12 men diagnosed, to prevent one prostate-cancer death ^[22]. At the 9-year mark the relative cut looked bigger (20 percent; rate ratio 0.80; 95 percent CI 0.65 to 0.98), but the ratio looked much worse: about 1,410 invited and 48 treated per death prevented ^[17]. The balance improves with time. It is still a lot of biopsies and treatments (with the risk of incontinence and impotence) per life saved.

The overdiagnosis can be quantified. Modelling from the ERSPC Rotterdam data puts it at about half: in screening from age 55 to 67, roughly 48 to 50 percent of screen-detected cancers would never have surfaced in the man's lifetime ^[23]. That is the core of the overdiagnosis and overtreatment debate. So this is a genuine trade-off, not a free good.

The German status. The S3-Leitlinie Prostatakarzinom (the highest-quality tier of German guideline, finalized July 2025) now recommends risk-adapted PSA-based early detection for men from age 45. It comes after outcome-open counseling, meaning you and your doctor decide together ^[18]. The guideline advises against the digital rectal exam (the finger exam) as a standalone screening tool ^[18]. Despite this, PSA screening is still an IGeL or self-pay service, not yet a GKV benefit. From age 45, statutory insurance still pays only for an annual prostate palpation. In October 2025, the Gemeinsamer Bundesausschuss (G-BA, the body that decides what statutory insurance covers) opened a review of risk-adapted screening with PSA and MRI for men 50 to 70. A decision is expected by about October 2027 ^[18].

That leaves the old worry that TRT causes prostate cancer. In carefully screened men, the best trial found no increase, but monitoring stays necessary. The TRAVERSE prostate-safety substudy followed 5,204 men with diagnosed low testosterone for about 14,304 person-years (all years of follow-up added together) ^[19]:

• High-grade prostate cancer: 0.19 percent on testosterone versus 0.12 percent on placebo. The difference was not significant (hazard ratio 1.62; 95 percent CI 0.39 to 6.77; p = 0.51). The wide range shows how rare these cancers were in both groups, so a real increase cannot be fully ruled out.
• Prostate cancer of any grade and other prostate events: also no significant difference.

The trial excluded men with a PSA above 3 ng/mL, treatment averaged under two years, and PSA rose more on testosterone ^[19]. That weakens the old dogma that testosterone feeds prostate cancer. PSA and prostate checks before and during treatment stay standard all the same. We go deeper on the TRT part in the TRT and HRT deep-dive guide. How and when screening is sensibly timed sits in the men 40-plus hub.

With a medical indication, the insurer pays, and you only carry the co-pay of 5 to 10 euros. Without an indication it is self-pay, and the drug alone then runs roughly 30 to 60 euros per month. The deciding factor is whether a genuine hypogonadism is documented.

TRT (testosterone replacement therapy) is a treatment for diagnosed hypogonadism, not a lifestyle upgrade. Genuine late-onset hypogonadism is uncommon: about 2.1 percent of men aged 40 to 79, rising with age from 0.1 percent (40 to 49) to 5.1 percent (70 to 79) ^[13]. So most men with low energy do NOT have a treatable testosterone deficiency. That is the most important filter against the everyone-needs-TRT marketing.

Heart safety, when TRT is indicated, is reassuring but not risk-free. TRAVERSE enrolled about 5,200 men with diagnosed low testosterone (total testosterone below 300 ng/dL on two fasting tests) and high cardiovascular risk ^[20]. Testosterone gel on the skin did no worse than placebo for major heart events (7.0 versus 7.3 percent). That is what "non-inferior" means ^[20]. But some problems were more common on testosterone ^[20]:

• atrial fibrillation (an irregular heartbeat): 3.5 versus 2.4 percent
• pulmonary embolism (a blood clot in the lung): 0.9 versus 0.5 percent
• acute kidney injury: 2.3 versus 1.5 percent

A TRAVERSE substudy also found more fractures on testosterone, not fewer (3.5 versus 2.5 percent) ^[24]. Meaning: monitored, not casual.

The GKV reimburses TRT when the hypogonadism is documented. Once two measurements confirm the low value, statutory insurance covers diagnosis and therapy. Per item you usually pay only the standard co-pay: 10 percent of the price, at least 5 and at most 10 euros (as of 2026) ^[21]. Without a hypogonadism diagnosis, a doctor may not prescribe testosterone for anti-aging or lifestyle at the GKV's expense. If they do, the insurer can claw the money back from the doctor (a Regress).

Without a medical indication it is self-pay. Boosting a normal man's testosterone is off-label (outside the approved use) and not reimbursed. Private TRT clinics charge for the consult, labs and drug separately. For a rough sense of the preparations:

Preparation	Form	Dosing	Cost range (self-pay)
Nebido (testosterone undecanoate)	Injection	1000 mg every ~10 to 14 weeks	~140 euros per vial, about 1.4 to 2.0 euros per day
Testogel / Tostran	Daily gel	Daily application	same order of magnitude, pack price not publicly listed

The gel per-day prices are not published in German databases and must be asked at the pharmacy, so treat them as an estimate. Out of pocket, about 30 to 60 euros per month is a fair self-pay band for the drug, depending on preparation and dose. Treat it as a rough estimate, not a hard number.

The practical fork for you. Symptoms plus two low morning values? See a doctor. The workup and, if indicated, the TRT are an insurance matter. No symptoms or normal testosterone? Then no TRT. Work on sleep, weight and alcohol instead. The full TRT mechanics (protocols, evidence, the DACH reality) sit in the TRT and HRT deep-dive guide.